Biotech Co. Pens $18.5M Deal In Investor Fraud Class Action
Investors in Osiris Therapeutics Inc. told a Maryland federal judge on Tuesday that they had reached an $18.5 million settlement with the biotech research company over allegations it artificially inflated reported revenues...To view the full article, register now.
Already a subscriber? Click here to view full article